indazoles has been researched along with Acute Myelogenous Leukemia in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 19 (76.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexe, G; Armstrong, SA; Blachly, JS; Byrd, JC; Chu, SH; Cremer, A; Ellegast, JM; Frank, ES; Goodale, A; Häupl, B; Mohr, S; Oellerich, T; Piccioni, F; Pikman, Y; Rao, AV; Robichaud, A; Ross, L; Stegmaier, K; Walker, AR | 1 |
| Bhatnagar, B; Blachly, JS; Blum, WG; Byrd, JC; Crosswell, HE; Lin, TL; Liu, J; Long, L; Mims, AS; Minden, MD; Munugalavadla, V; Oellerich, T; Orwick, S; Pan, Y; Rao, AV; Serve, H; Walker, AR; Zhang, D | 1 |
| Stretton, O | 1 |
| Bonvini, P; Fagan, PC; Frasson, C; Germano, G; Li, G; Pomari, E; Silverman, I; Smith, KM; Walsh, C | 1 |
| Chen, B; Zhou, F | 1 |
| Berdel, WE; Bormann, E; Brümmendorf, TH; Crysandt, M; Gerss, J; Hartmann, W; Kessler, T; Kirsch, A; Koschmieder, S; Lenz, G; Mikesch, JH; Müller-Tidow, C; Pohlen, M; Schliemann, C; Stelljes, M; Vehring, K; von Stillfried, S; Wardelmann, E | 1 |
| Bruserud, Ø; Hatfield, KJ; Nepstad, I; Reikvam, H | 1 |
| Andreeff, M; Benito, J; Ciurea, SO; Jin, L; Kojima, K; Konopleva, M; McQueen, T; Miida, T; Ruvolo, V; Shikami, M; Tabe, Y; Wang, RY | 1 |
| Bruserud, Ø; Ersvaer, E; Hatfield, KJ; Holdhus, R; Poulain, L; Reikvam, H; Skrede, S; Tamburini, J | 1 |
| Galanis, A; Levis, M | 1 |
| Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E | 1 |
| Han, Y; Li, P; Song, K; Xie, Z; Xu, X; Zhang, L; Zhao, Y; Zhou, L; Zhou, P | 1 |
| Fukutake, S; Kurosu, T; Miura, O; Nagao, T; Nogami, A; Okada, K; Oshikawa, G; Umezawa, Y | 1 |
| Cogle, CR; Drusbosky, L; Gars, E; McGee, C; Meacham, A; Scott, EW; Trujillo, A; Wise, E | 1 |
| Fu, Y; Gao, M; Wang, G; Xu, L; Zhang, Y | 1 |
| Assal, A; Bachegowda, L; Bartenstein, M; Bhagat, T; Bhattacharyya, S; Boultwood, J; Brown, S; Burgess, LE; Chantry, D; Garrus, J; Giricz, O; Gordon-Mitchell, S; Gross, S; Guha, C; Hogeland, G; Mantzaris, I; Morrone, K; Munson, M; Nwankwo, G; Pellagatti, A; Platanias, L; Pradhan, K; Ramachandra, N; Rizzi, J; Rodriguez, M; Schinke, C; Shahnaz, S; Shastri, A; Steidl, U; Sukrithan, V; Verma, A; Winski, SL; Wollenberg, L; Wright, D; Yu, Y; Zou, Y | 1 |
| Albert, DH; Bi, C; Chen, CS; Chng, WJ; Davidsen, SK; Glaser, KB; Janakakumara, JV; Liu, SC; Palaniyandi, S; Poon, LF; Tay, KG; Xie, Z; Yu, H; Zhou, J | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Ajenjo, N; Albarán, MI; Alfonso, P; Becerra, M; Bischoff, JR; Blanco-Aparicio, C; Carnero, A; Collazo, AM; Corrionero, A; Fominaya, J; Leal, JF; Lima, FR; Lopez, AR; Mateos, G; Oyarzabal, J; Palacios, I; Pastor, J; Pequeño, B; Pevarello, P; Quiñones, H; Reymundo, MI | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Chang, CY; Chang, KY; Chang, TY; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Hsieh, SY; Hsu, JT; Huang, YL; Jiaang, WT; Lin, WH; Yeh, TK; Yen, KJ; Yen, SC | 1 |
| Albert, DH; Carlson, DM; Dudley, M; Enschede, S; Glaser, K; Hogge, D; Koh, LP; Li, X; McKeegan, E; Pradhan, R; Stock, W; Wang, ES; Yee, K | 1 |
| Andreeff, M; Borthakur, G; Jin, L; Kantarjian, H; Konopleva, M; Lu, H; Miida, T; Tabe, Y | 1 |
| Albert, DH; Bouska, JJ; Chang, JC; Dai, Y; Davidsen, SK; Glaser, KB; Guo, J; Hartandi, K; Johnson, EF; Li, J; Marcotte, PA; Michaelides, MR; Moore, TB; Osterling, DJ; Owen McCall, J; Pease, LJ; Priceman, SJ; Rhodes, K; Sakamoto, KM; Shah, N; Shankar, DB; Soni, N; Tapang, P; Wei, RQ | 1 |
| Albert, DH; Bi, C; Chen, CS; Davidsen, SK; Glaser, KB; Jasinghe, VJ; Khng, J; Lu, Y; Neo, CH; Pan, M; Poon, LF; Xie, Z; Yeoh, AE; Yu, H; Zhou, J | 1 |
1 review(s) available for indazoles and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.
Topics: Benzamides; ETS Translocation Variant 6 Protein; Gene Rearrangement; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-ets; Repressor Proteins; Staurosporine; Tumor Microenvironment | 2018 |
3 trial(s) available for indazoles and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Topics: Adult; Cytarabine; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Ecotropic Viral Integration Site 1 Protein; Pyrazines; Syk Kinase | 2020 |
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow; Female; Gastrointestinal Diseases; Humans; Indazoles; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Microvessels; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome; Tumor Microenvironment | 2019 |
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Recurrence; Treatment Outcome | 2012 |
21 other study(ies) available for indazoles and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Indazoles; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Mutagenesis, Site-Directed; Mutation; Open Reading Frames; Primary Cell Culture; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Syk Kinase; Xenograft Model Antitumor Assays | 2020 |
EHA 2021 Virtual Congress.
Topics: Activin Receptors, Type II; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; beta-Thalassemia; Graft vs Host Disease; Hematologic Diseases; Humans; Immunoglobulin Fc Fragments; Indazoles; Interleukin-1 Receptor-Associated Kinases; Internet; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Fusion Proteins; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2021 |
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Topics: Animals; Benzamides; Cell Line, Tumor; Female; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Zebrafish | 2018 |
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cytogenetics; Cytokines; Female; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Sirolimus; Stromal Cells; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult | 2013 |
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
Topics: Apoptosis; Biphenyl Compounds; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hypoxia; Indazoles; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Phosphoinositide-3 Kinase Inhibitors; Piperazines; RNA Interference; Sulfonamides; Tumor Microenvironment | 2013 |
Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Topics: Antineoplastic Agents; cdc25 Phosphatases; Cell Proliferation; Cell Survival; Cluster Analysis; Cytokines; Gene Expression Regulation, Leukemic; Humans; Indazoles; Leukemia, Myeloid, Acute; Pharmacogenetics; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Transcriptome; Treatment Outcome | 2014 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases | 2014 |
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1 (HS3ST3B1) promotes angiogenesis and proliferation by induction of VEGF in acute myeloid leukemia cells.
Topics: Axitinib; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Sulfotransferases; Vascular Endothelial Growth Factor A | 2015 |
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Carrier Proteins; Caspase 9; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; Eukaryotic Initiation Factors; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Pimozide; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Sulfonamides; TOR Serine-Threonine Kinases | 2015 |
Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Endothelial Cells; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sulfonamides; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Proliferation; Cells, Cultured; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; U937 Cells | 2016 |
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Proportional Hazards Models; Receptor, TIE-2; Urea | 2016 |
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.
Topics: Animals; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Epoxy Compounds; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Phenylurea Compounds; Sesquiterpenes; Signal Transduction; STAT3 Transcription Factor; Substrate Specificity; Survivin; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Leukemia, Myeloid, Acute; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Sulfonamides | 2011 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.
Topics: Animals; Benzamides; Cell Proliferation; fms-Like Tyrosine Kinase 3; HEK293 Cells; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sulfonamides; Tumor Cells, Cultured | 2012 |
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cellular Microenvironment; Coculture Techniques; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-pim-1; Sorafenib; Stromal Cells; Sulfonamides | 2013 |
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; G1 Phase; Hematopoietic Stem Cells; Humans; Indazoles; K562 Cells; Ki-67 Antigen; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-pim-1; Resting Phase, Cell Cycle; STAT5 Transcription Factor; Tumor Stem Cell Assay; U937 Cells | 2007 |
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2008 |